Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

被引：12

作者：

Benza, Raymond L. ^{[1
]}

Langleben, David ^{[2
]}

Hemnes, Anna R. ^{[3
]}

Noordegraaf, Anton Vonk ^{[4
]}

Rosenkranz, Stephan ^{[5
]}

Thenappan, Thenappan ^{[6
]}

Hassoun, Paul M. ^{[7
]}

Preston, Ioana R. ^{[8
]}

Ghio, Stefano ^{[9
]}

Badagliacca, Roberto ^{[10
]}

Vizza, Carmine D. ^{[10
]}

Lang, Irene M. ^{[11
]}

Meier, Christian ^{[12
]}

Gruenig, Ekkehard ^{[13
]}

机构：

[1] Ohio State Univ Wexner Med Ctr, Dept Med, Columbus, OH 43210 USA

[2] McGill Univ, Jewish Gen Hosp, Ctr Pulm Vasc Dis, Div Cardiol, Montreal, PQ, Canada

[3] Vanderbilt Univ Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA

[4] Vrije Univ Amsterdam Med Ctr, Pulm Dis, Amsterdam, Netherlands

[5] Cologne Univ Heart Ctr, Dept Cardiol, Cologne, Germany

[6] Univ Minnesota, Dept Med, Cardiovasc Div, Minneapolis, MN USA

[7] Johns Hopkins Univ, Pulm & Crit Care Med, Baltimore, MD USA

[8] Tufts Med Ctr, Pulm Crit Care & Sleep Med Div, Boston, MA USA

[9] Fdn IRCCS Policlin San Matteo, Div Cardiol, Pavia, Italy

[10] Sapienza Univ, Dept Cardiol, Rome, Italy

[11] Med Univ Vienna, Allgemeines Krankenhaus, Dept Internal Medicine 2, Div Cardiol, Vienna, Austria

[12] Global Med Affairs, Bayer AG, Berlin, Germany

[13] Heidelberg Univ Hosp, Ctr Pulm Hypertens, Thoraxklin Heidelberg gGmbH, Heidelberg, Germany

来源：

EUROPEAN RESPIRATORY REVIEW | 2022年 / 31卷 / 166期

关键词：

SOLUBLE GUANYLATE-CYCLASE; ENDOTHELIN-RECEPTOR ANTAGONIST; RIGHT HEART; EXERCISE CAPACITY; BOSENTAN TREATMENT; PROGNOSTIC VALUE; SILDENAFIL; PARAMETERS; MANAGEMENT; SURVIVAL;

D O I：

10.1183/16000617.0061-2022

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.

引用

页数：12

共 50 条

[21] Right Ventricular Dyssynchrony in Patients With Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Yamagata, Yuki
Ikeda, Satoshi
Kojima, Sanae
Ueno, Yuki
Nakata, Tomoo
Koga, Seiji
Ohno, Chikara
Yonekura, Tsuyoshi
Yoshimuta, Tsuyoshi
Minami, Takako
Kawano, Hiroaki
Maemura, Koji
CIRCULATION JOURNAL, 2022, 86 (06) : 936 - +
[22] Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Saleh, S.
Becker, C.
Frey, R.
Mueck, W.
EUROPEAN HEART JOURNAL, 2014, 35 : 72 - 72
[23] Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Anderson, Ryan J.
Malhotra, Atul
Kim, Nick H.
JOURNAL OF THORACIC DISEASE, 2016, 8 : S562 - S565
[24] Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Saleh, Soundos
Becker, Corina
Frey, Reiner
Mueck, Wolfgang
PULMONARY CIRCULATION, 2016, 6 : S86 - S96
[25] Riociguat for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Update from the EXPERT Registry
Klose, H.
Gall, H.
Ghofrani, H.
Gruenig, E.
Humbert, M.
Simonneau, G.
Halank, M.
Langleben, D.
Snijder, R. J.
Escribano, P.
Mielniczuk, L. M.
Lange, T.
Vachiery, J.
Wirtz, H.
Helmersen, D. S.
Tsangaris, I.
Barbera, J. A.
Pepke-Zaba, J.
Boonstra, A.
Rosenkranz, S.
Ulrich, S.
Mascherbauer, R.
Delcroix, M.
Jansa, P.
Gomez Sanchez, M. A.
Klotsche, J.
Meier, C.
Pittrow, D.
Hoeper, M. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[26] Shift in transcriptional landscape of human right ventricle in chronic thromboembolic pulmonary arterial hypertension
Jafari, L.
Doerr, O.
Chelladurai, P.
Pullamsetti, S. S.
Troidl, C.
Keller, T.
Guenther, S.
Gruen, D.
Keranov, S.
Kriechbaum, S.
Liebetrau, C.
Mayer, E.
Seeger, W.
Hamm, C. W.
Nef, H. M.
EUROPEAN HEART JOURNAL, 2020, 41 : 2230 - 2230
[27] Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
Humbert, M.
EUROPEAN RESPIRATORY REVIEW, 2010, 19 (115): : 59 - 63
[28] Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Marra, Alberto M.
Egenlauf, Benjamin
Ehlken, Nicola
Fischer, Christine
Eichstaedt, Christina
Nagel, Christian
Bossone, Eduardo
Cittadini, Antonio
Halank, Michael
Gall, Henning
Olsson, Karen M.
Lange, Tobias J.
Gruenig, Ekkehard
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 195 : 19 - 26
[29] Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Kim, N.
EUROPEAN RESPIRATORY REVIEW, 2010, 19 (115): : 68 - 71
[30] Riociguat for Chronic Thromboembolic Pulmonary Hypertension - Initial Experience
Haddad, Ruba
Mielniczuk, Lisa
Pugliese, Carolyn
Chandy, George
Stewart, Duncan
Contreras-Dominguez, Vladimir
Davies, Ross
JOURNAL OF CARDIAC FAILURE, 2015, 21 (08) : S71 - S72

← 1 2 3 4 5 →